Cardiovascular Systems (NSDQ:CSII) touted today that the first patients in the U.S. were treated with the OrbusNeich Teleport microcatheter.
The device, which recently won 510(k) clearance with the FDA, enables safe guidewire exchange during cardiovascular procedures. The Teleport product features a robust tip to provide access to challenging lesions, according to Cardiovascular Systems.
Dr. Annapoorna Kini, director of the Cardiac Catheterization Lab at Mount Sinai Medical Center and Dr. Emmanouil Brilakis of the Minneapolis Heart Institute treated the first U.S. patients with Teleport.
“I am excited and honored to be the first to use Teleport microcatheter in the United States. Teleport allowed me to deliver the microcatheter easily through tortuous coronary vasculature while maintaining catheter position for guidewire exchange treating a complex chronic total occlusion,” Dr. Kini said in prepared remarks.
“I had the opportunity to use the Teleport Microcatheter in Europe and was impressed by its balance of deliverability and support. Teleport’s robust tip design is unique, enabling access to tight lesions while providing the torqueability necessary to treat very challenging lesions. I’m excited to have this device available to treat my patients here in the United States,” Dr. Brilakis added.
“We are committed to building a comprehensive cardiovascular company and leveraging our commercial footprint and clinical value to become the partner of choice in the revascularization of patients with complex peripheral and coronary artery disease. The clearance of the Teleport Microcatheter complements our emphasis on providing advanced solutions for the most difficult coronary and peripheral lesions,” chairman, president & CEO Scott Ward said.
